Can India's Borrow And Treat Market Move The Access Needle?
This article was originally published in Scrip
Are innovative financing schemes to improve access to breakthrough, expensive drugs the way forward in self-pay markets like India? And can microfinance firms move the needle in such markets marked by low health insurance penetration?
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.